Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers By Watertime - September 21, 2026 4 Post Content RELATED ARTICLESMORE FROM AUTHOR Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health Weekly Psychedelic Policy Briefing: October 5, 2026
